Although type 2 diabetes and obesity have been effectively treated with GLP-1 receptor agonists, their role in pregnancy and breastfeeding has been a controversial debate due to potential risks to the mother’s health and fetal outcomes (87). This evidence concerns the gene GLP1R and type 2 diabetes mellitus.